Novavax CEO Says Covid-19 Vaccine Could Be Distributed by End of Year

The video discusses the progress of a vaccine development, highlighting the completion of preclinical trials and the start of phase 1-2 clinical trials in Australia. It outlines the expected timeline for vaccine efficacy and distribution, aiming for emergency use by the end of the year. The video explains the advantages of a protein-based approach, citing previous successes with SARS and MERS vaccines. It also covers the acquisition of a manufacturing facility in the Czech Republic to scale production, emphasizing the need for multiple vaccines globally due to scalability challenges.

What is the significance of the acquisition of the manufacturing facility in the Czech Republic?

What challenges do vaccine manufacturers face in terms of scalability?

What factors must be considered to ensure a vaccine is safe and effective?